Affymetrix Appoints Masao Yoneyama as General Manager of Japan Operations

16-Oct-2006

Affymetrix Inc. announced that it has named Masao Yoneyama, Ph.D., General Manager of Japan Operations. As part of this role, Dr. Yoneyama has been elected as Affymetrix' representative director for Japan and will be responsible for growing the business across the country.

Dr. Yoneyama brings 20 years of experience in the life sciences industry to Affymetrix. His specific areas of expertise are toxicogenomics, pharmacogenomics and molecular diagnostics. He joins Affymetrix from Daiichi Pure Chemicals Co., Ltd., where he was the general manager of business development. He was responsible for research and development and creating new business opportunities in several different areas, including personalized medicine, point-of-care testing, food safety and toxicology.

Dr. Yoneyama holds a bachelor's degree in chemistry, Master of Science degree and a doctorate in toxicology from Utah State University. He also holds a diploma from Ikutoku Technical College (Japan) in chemical engineering.

Other news from the department people

Most read news

More news from our other portals

Fighting cancer: latest developments and advances

See the theme worlds for related content

Topic world Diagnostics

Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.

10+ products
4 whitepaper
10+ brochures
View topic world
Topic world Diagnostics

Topic world Diagnostics

Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.

10+ products
4 whitepaper
10+ brochures